191 related articles for article (PubMed ID: 26636425)
1. Brief Report: Monoclonal Gammopathy and Risk of Lymphoma and Multiple Myeloma in Patients With Primary Sjögren's Syndrome.
Tomi AL; Belkhir R; Nocturne G; Desmoulins F; Berge E; Pavy S; Miceli-Richard C; Mariette X; Seror R
Arthritis Rheumatol; 2016 May; 68(5):1245-50. PubMed ID: 26636425
[TBL] [Abstract][Full Text] [Related]
2. Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome.
Nocturne G; Virone A; Ng WF; Le Guern V; Hachulla E; Cornec D; Daien C; Vittecoq O; Bienvenu B; Marcelli C; Wendling D; Amoura Z; Dhote R; Lavigne C; Fior R; Gottenberg JE; Seror R; Mariette X
Arthritis Rheumatol; 2016 Apr; 68(4):977-85. PubMed ID: 26606524
[TBL] [Abstract][Full Text] [Related]
3. European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients.
Seror R; Gottenberg JE; Devauchelle-Pensec V; Dubost JJ; Le Guern V; Hayem G; Fauchais AL; Goeb V; Hachulla E; Hatron PY; Larroche C; Morel J; Pedriger A; Puechal X; Rist S; Saraux A; Sene D; Sibilia J; Vittecoq O; Zarnitsky C; Labetoulle M; Ravaud P; Mariette X
Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1358-64. PubMed ID: 23436737
[TBL] [Abstract][Full Text] [Related]
4. CXCL13 and CCL11 Serum Levels and Lymphoma and Disease Activity in Primary Sjögren's Syndrome.
Nocturne G; Seror R; Fogel O; Belkhir R; Boudaoud S; Saraux A; Larroche C; Le Guern V; Gottenberg JE; Mariette X
Arthritis Rheumatol; 2015 Dec; 67(12):3226-33. PubMed ID: 26359802
[TBL] [Abstract][Full Text] [Related]
5. Sjögren's disease activity associates with cardiovascular disease and monoclonal gammopathy: a university cohort study of disease activity and comorbidities.
Bohman BR; Dowds HS; Blagogee TE; Ike RW; Hansen KE; McCoy SS
Clin Rheumatol; 2024 Mar; 43(3):1093-1101. PubMed ID: 38326676
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal gammopathy related to Sjögren syndrome: a key marker of disease prognosis and outcomes.
Brito-Zerón P; Retamozo S; Gandía M; Akasbi M; Pérez-De-Lis M; Diaz-Lagares C; Bosch X; Bové A; Pérez-Alvarez R; Soto-Cárdenas MJ; Sisó A; Ramos-Casals M
J Autoimmun; 2012 Aug; 39(1-2):43-8. PubMed ID: 22297146
[TBL] [Abstract][Full Text] [Related]
7. Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry).
Ramos-Casals M; Brito-Zerón P; Solans R; Camps MT; Casanovas A; Sopeña B; Díaz-López B; Rascón FJ; Qanneta R; Fraile G; Pérez-Alvarez R; Callejas JL; Ripoll M; Pinilla B; Akasbi M; Fonseca E; Canora J; Nadal ME; de la Red G; Fernández-Regal I; Jiménez-Heredia I; Bosch JA; Ayala MD; Morera-Morales L; Maure B; Mera A; Ramentol M; Retamozo S; Kostov B; ;
Rheumatology (Oxford); 2014 Feb; 53(2):321-31. PubMed ID: 24162151
[TBL] [Abstract][Full Text] [Related]
8. Comorbidities in Patients With Primary Sjögren's Syndrome and Systemic Lupus Erythematosus: A Comparative Registries-Based Study.
Rúa-Figueroa I; Fernández Castro M; Andreu JL; Sanchez-Piedra C; Martínez-Taboada V; Olivé A; López-Longo J; Rosas J; Galindo M; Calvo-Alén J; Fernández-Nebro A; Alonso F; Rodríguez-Lozano B; Alberto García Vadillo J; Menor R; Narváez FJ; Erausquin C; García-Aparicio Á; Tomero E; Manrique-Arija S; Horcada L; Uriarte E; Gil S; Blanco R; López-González R; Boteanu A; Freire M; Galisteo C; Rodríguez-Gómez M; Díez-Álvarez E; Pego-Reigosa JM;
Arthritis Care Res (Hoboken); 2017 Jan; 69(1):38-45. PubMed ID: 27564390
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of systemic activity of pediatric primary Sjögren's syndrome by EULAR Sjögren's syndrome disease activity index (ESSDAI).
Kobayashi I; Okura Y; Ueki M; Tozawa Y; Takezaki S; Yamada M; Ariga T
Mod Rheumatol; 2019 Jan; 29(1):130-133. PubMed ID: 29529894
[TBL] [Abstract][Full Text] [Related]
10. Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients.
Brito-Zerón P; Kostov B; Solans R; Fraile G; Suárez-Cuervo C; Casanovas A; Rascón FJ; Qanneta R; Pérez-Alvarez R; Ripoll M; Akasbi M; Pinilla B; Bosch JA; Nava-Mateos J; Díaz-López B; Morera-Morales ML; Gheitasi H; Retamozo S; Ramos-Casals M;
Ann Rheum Dis; 2016 Feb; 75(2):348-55. PubMed ID: 25433020
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of and factors associated with increased arterial stiffness in patients with primary Sjögren's syndrome.
Sabio JM; Sánchez-Berná I; Martinez-Bordonado J; Vargas-Hitos JA; Navarrete-Navarrete N; Expósito Ruíz M; Jiménez-Alonso J
Arthritis Care Res (Hoboken); 2015 Apr; 67(4):554-62. PubMed ID: 25303669
[TBL] [Abstract][Full Text] [Related]
12. Severe intestinal dysbiosis is prevalent in primary Sjögren's syndrome and is associated with systemic disease activity.
Mandl T; Marsal J; Olsson P; Ohlsson B; Andréasson K
Arthritis Res Ther; 2017 Oct; 19(1):237. PubMed ID: 29065905
[TBL] [Abstract][Full Text] [Related]
13. Hyperviscosity in primary Sjögren's syndrome: clinical implications.
Hernández-Molina G; Bermúdez-Bermejo P
Int J Rheum Dis; 2017 Jan; 20(1):84-89. PubMed ID: 26807556
[TBL] [Abstract][Full Text] [Related]
14. Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren's syndrome: prevalence, clinical and laboratory associations.
Gravani F; Papadaki I; Antypa E; Nezos A; Masselou K; Ioakeimidis D; Koutsilieris M; Moutsopoulos HM; Mavragani CP
Arthritis Res Ther; 2015 Apr; 17(1):99. PubMed ID: 25886059
[TBL] [Abstract][Full Text] [Related]
15. Elevated levels of faecal calprotectin in primary Sjögren's syndrome is common and associated with concomitant organic gastrointestinal disease.
Andréasson K; Ohlsson B; Mandl T
Arthritis Res Ther; 2016 Jan; 18():9. PubMed ID: 26759247
[TBL] [Abstract][Full Text] [Related]
16. Young onset of primary Sjögren's syndrome: clinical and immunological characteristics.
Ramos-Casals M; Cervera R; Font J; García-Carrasco M; Espinosa G; Reino S; Pallarés L; Ingelmo M
Lupus; 1998; 7(3):202-6. PubMed ID: 9607645
[TBL] [Abstract][Full Text] [Related]
17. Severe, life-threatening phenotype of primary Sjögren's syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry).
Flores-Chávez A; Kostov B; Solans R; Fraile G; Maure B; Feijoo-Massó C; Rascón FJ; Pérez-Alvarez R; Zamora-Pasadas M; García-Pérez A; Lopez-Dupla M; Duarte-Millán MÁ; Ripoll M; Fonseca-Aizpuru E; Guisado-Vasco P; Pinilla B; de-la-Red G; Chamorro AJ; Morcillo C; Fanlo P; Soto-Cárdenas MJ; Retamozo S; Ramos-Casals M; Brito-Zerón P;
Clin Exp Rheumatol; 2018; 36 Suppl 112(3):121-129. PubMed ID: 30156546
[TBL] [Abstract][Full Text] [Related]
18. Serological lymphocytic activity and patient-reported outcomes in Sjögren's syndrome.
Jülich M; Kanne AM; Sehnert B; Budweiser S; Voll RE; Kollert F
Clin Rheumatol; 2018 Sep; 37(9):2361-2366. PubMed ID: 29858711
[TBL] [Abstract][Full Text] [Related]
19. Anti-centromere antibody-positive Sjögren's syndrome: A distinct clinical subgroup?
Lee KE; Kang JH; Lee JW; Wen L; Park DJ; Kim TJ; Park YW; Lee SS
Int J Rheum Dis; 2015 Sep; 18(7):776-82. PubMed ID: 26179502
[TBL] [Abstract][Full Text] [Related]
20. Overlap of ACA-positive systemic sclerosis and Sjögren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma.
Baldini C; Mosca M; Della Rossa A; Pepe P; Notarstefano C; Ferro F; Luciano N; Talarico R; Tani C; Tavoni AG; Bombardieri S
Clin Exp Rheumatol; 2013; 31(2):272-80. PubMed ID: 23343785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
